3 news items
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
ALGS
5 Jun 24
Title: In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
ALGS
22 May 24
pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver
- Prev
- 1
- Next